Heta S. Desai

This paper uses chemoproteogenomics to identify gain-of-cysteine variants in cancer and healthy genomes, revealing their prevalence and potential for drug targeting.

The paper identifies proteoform-selective caspase-2 inhibitors using chemoproteomics, revealing a unique non-catalytic cysteine and validating their selectivity and activity.

This study maps chemoproteomic-detected amino acids to genomic coordinates, revealing that reactive cysteine codons are enriched for deleterious genetic variants.